Brief: Gilead Sciences Expands Liver Portfolio With Acquisition Of Cymabay Therapeutics

CymaBay Therapeutics

12/02/2024 13:34

Feb 12 (Reuters) - Cymabay Therapeutics Inc  CBAY.O :
    * GILEAD SCIENCES EXPANDS LIVER PORTFOLIO WITH ACQUISITION
OF
CYMABAY THERAPEUTICS
    * SELADELPAR PHASE 3 DATA DEMONSTRATES A BEST-IN-DISEASE
PROFILE
FOR SECOND-LINE PBC
    * GILEAD WILL ACQUIRE CYMABAY FOR $32.50 PER SHARE IN CASH
OR A
TOTAL EQUITY VALUE OF $4.3 BILLION.
    * PROPOSED DEAL FOR $4.3 BILLION
    * ACQUISITION EXPANDS GILEAD'S LONG-STANDING COMMITMENT TO
PATIENTS WITH LIVER DISEASES
    * TRANSACTION WAS APPROVED BY BOTH GILEAD AND CYMABAY BOARDS
OF
DIRECTORS
    * TRANSACTION WILL BE APPROXIMATELY NEUTRAL TO EARNINGS PER
SHARE
IN 2025 AND SIGNIFICANTLY ACCRETIVE THEREAFTE

Source text for Eikon:  ID:nBw8gmfcLa 
Further company coverage:  CBAY.O 

 ((Reuters.Briefs@thomsonreuters.com;))